James Trussell1, Deborah Nucatola2, Mary Fjerstad3, E Steve Lichtenberg4. 1. Office of Population Research, Princeton University, Princeton, NJ 08544, USA; The Hull York Medical School, University of Hull, Hull HU6 1RX, England. Electronic address: trussell@princeton.edu. 2. Planned Parenthood Federation of America, New York, NY 10001, USA. 3. WomanCare Global, San Diego, CA 92122, USA. 4. Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Abstract
BACKGROUND: From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24-48 h later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions. METHODS: We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies. RESULTS: The mortality rate dropped significantly in the 81-month period after the joint change to (1) buccal misoprostol replacing vaginal misoprostol and (2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66-month period), from 1.37/100,000 to 0.00/100,000, P=.013 (difference=1.37/100,000, 95% CI 0.47-4.03 per 100,000). CONCLUSION: The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage. SIGNIFICANCE: Deaths from infection following medical abortion declined to zero after a change in the regimen.
BACKGROUND: From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24-48 h later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions. METHODS: We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies. RESULTS: The mortality rate dropped significantly in the 81-month period after the joint change to (1) buccal misoprostol replacing vaginal misoprostol and (2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66-month period), from 1.37/100,000 to 0.00/100,000, P=.013 (difference=1.37/100,000, 95% CI 0.47-4.03 per 100,000). CONCLUSION: The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage. SIGNIFICANCE: Deaths from infection following medical abortion declined to zero after a change in the regimen.
Authors: Beverly Winikoff; Ilana G Dzuba; Mitchell D Creinin; William A Crowden; Alisa B Goldberg; Juliana Gonzales; Michelle Howe; Jeffrey Moskowitz; Linda Prine; Caitlin S Shannon Journal: Obstet Gynecol Date: 2008-12 Impact factor: 7.661
Authors: Marc Fischer; Julu Bhatnagar; Jeannette Guarner; Sarah Reagan; Jill K Hacker; Sharon H Van Meter; Vadims Poukens; David B Whiteman; Anthony Iton; Michele Cheung; David E Dassey; Wun-Ju Shieh; Sherif R Zaki Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Mary Fjerstad; Irving Sivin; E Steve Lichtenberg; James Trussell; Kelly Cleland; Vanessa Cullins Journal: Contraception Date: 2009-05-02 Impact factor: 3.375
Authors: Mary Fjerstad; James Trussell; Irving Sivin; E Steve Lichtenberg; Vanessa Cullins Journal: N Engl J Med Date: 2009-07-09 Impact factor: 91.245
Authors: Spyros A Kalams; Lisa M Rogers; Rita M Smith; Louise Barnett; Katie Crumbo; Shonda Sumner; Naomi Prashad; Kyle Rybczyk; Ginger Milne; Scot E Dowd; Erica Chong; Beverly Winikoff; David M Aronoff Journal: Eur J Contracept Reprod Health Care Date: 2016-09-16 Impact factor: 1.848